Johannes D Veldhuis1, George Ann Reynolds, Ali Iranmanesh, Cyril Y Bowers. 1. Endocrine Research Unit, Department of Internal Medicine, Clinical Translational Science Unit, Mayo Medical and Graduate Schools of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA. veldhuis.johannes@mayo.edu
Abstract
BACKGROUND: Ghrelin is a 28-amino acid acylated peptide that potentiates GHRH stimulation and opposes somatostatin inhibition acutely. Whether prolonged ghrelin administration can sustain physiological patterns of GH secretion remains unknown. HYPOTHESIS: Continuous delivery of ghrelin will amplify physiological patterns of GH secretion over 24 h. SUBJECTS: Men and women ages 29-69 yr, body mass indices 23-52 kg/m2, were included in the study. LOCATION: The study was performed at an academic medical center. METHODS: Twenty-four hour continuous sc infusion of saline vs. ghrelin (1 microg/kg.h) with frequent sampling was examined. Deconvolution and entropy analyses were performed. OUTCOMES: IGF-I concentrations were determined. Basal, pulsatile, nycthemeral, and entropic measures of GH secretion were calculated. RESULTS: Ghrelin infusion compared with saline infusion for 24 h elevated (median) acylated ghrelin, GH, and IGF-I concentrations by 8.1-fold (P < 0.001),11-fold (P < 0.001), and 1.4-fold (P = 0.002). GH secretory-burst mass and frequency increased by 6.6-fold (P = 0.004) and 1.7-fold (P < 0.001), respectively, resulting in a 12-fold increase in pulsatile GH secretion (P < 0.001). Interpulse variability decreased significantly (P = 0.046), whereas GH secretory-burst shape and half-life did not change. The amplitude of the nycthemeral GH rhythm increased by 3.4-fold (P < 0.001), and GH patterns became more irregular (higher approximate entropy P < 0.001). Combining GHRH with ghrelin was not an additive in driving GH secretion. CONCLUSIONS: Continuous ghrelin infusion for 24 h elevates acylated ghrelin, GH and IGF-I concentrations, and stimulates pulsatile, nycthemeral, and entropic modes of GH secretion. The consistency of outcomes in a heterogeneous cohort of adults suggests potentially broad utility of this physiological secretagogue in hyposomatotropic states.
BACKGROUND:Ghrelin is a 28-amino acid acylated peptide that potentiates GHRH stimulation and opposes somatostatin inhibition acutely. Whether prolonged ghrelin administration can sustain physiological patterns of GH secretion remains unknown. HYPOTHESIS: Continuous delivery of ghrelin will amplify physiological patterns of GH secretion over 24 h. SUBJECTS:Men and women ages 29-69 yr, body mass indices 23-52 kg/m2, were included in the study. LOCATION: The study was performed at an academic medical center. METHODS: Twenty-four hour continuous sc infusion of saline vs. ghrelin (1 microg/kg.h) with frequent sampling was examined. Deconvolution and entropy analyses were performed. OUTCOMES: IGF-I concentrations were determined. Basal, pulsatile, nycthemeral, and entropic measures of GH secretion were calculated. RESULTS:Ghrelin infusion compared with saline infusion for 24 h elevated (median) acylated ghrelin, GH, and IGF-I concentrations by 8.1-fold (P < 0.001),11-fold (P < 0.001), and 1.4-fold (P = 0.002). GH secretory-burst mass and frequency increased by 6.6-fold (P = 0.004) and 1.7-fold (P < 0.001), respectively, resulting in a 12-fold increase in pulsatile GH secretion (P < 0.001). Interpulse variability decreased significantly (P = 0.046), whereas GH secretory-burst shape and half-life did not change. The amplitude of the nycthemeral GH rhythm increased by 3.4-fold (P < 0.001), and GH patterns became more irregular (higher approximate entropy P < 0.001). Combining GHRH with ghrelin was not an additive in driving GH secretion. CONCLUSIONS: Continuous ghrelin infusion for 24 h elevates acylated ghrelin, GH and IGF-I concentrations, and stimulates pulsatile, nycthemeral, and entropic modes of GH secretion. The consistency of outcomes in a heterogeneous cohort of adults suggests potentially broad utility of this physiological secretagogue in hyposomatotropic states.
Authors: H Pijl; J G Langendonk; J Burggraaf; M Frölich; A F Cohen; J D Veldhuis; A E Meinders Journal: J Clin Endocrinol Metab Date: 2001-11 Impact factor: 5.958
Authors: J D Veldhuis; M L Johnson; O L Veldhuis; M Straume; S M Pincus Journal: Am J Physiol Regul Integr Comp Physiol Date: 2001-12 Impact factor: 3.619
Authors: E Arvat; M Maccario; L Di Vito; F Broglio; A Benso; C Gottero; M Papotti; G Muccioli; C Dieguez; F F Casanueva; R Deghenghi; F Camanni; E Ghigo Journal: J Clin Endocrinol Metab Date: 2001-03 Impact factor: 5.958
Authors: A M Wren; L J Seal; M A Cohen; A E Brynes; G S Frost; K G Murphy; W S Dhillo; M A Ghatei; S R Bloom Journal: J Clin Endocrinol Metab Date: 2001-12 Impact factor: 5.958
Authors: F Roelfsema; N R Biermasz; R G Veldman; J D Veldhuis; M Frölich; W H Stokvis-Brantsma; J M Wit Journal: J Clin Endocrinol Metab Date: 2001-06 Impact factor: 5.958
Authors: Y Hataya; T Akamizu; K Takaya; N Kanamoto; H Ariyasu; M Saijo; K Moriyama; A Shimatsu; M Kojima; K Kangawa; K Nakao Journal: J Clin Endocrinol Metab Date: 2001-09 Impact factor: 5.958
Authors: Frederick Wasinski; Franco Barrile; João A B Pedroso; Paula G F Quaresma; Willian O Dos Santos; Edward O List; John J Kopchick; Mario Perelló; Jose Donato Journal: Endocrinology Date: 2021-07-01 Impact factor: 4.736
Authors: T D Müller; R Nogueiras; M L Andermann; Z B Andrews; S D Anker; J Argente; R L Batterham; S C Benoit; C Y Bowers; F Broglio; F F Casanueva; D D'Alessio; I Depoortere; A Geliebter; E Ghigo; P A Cole; M Cowley; D E Cummings; A Dagher; S Diano; S L Dickson; C Diéguez; R Granata; H J Grill; K Grove; K M Habegger; K Heppner; M L Heiman; L Holsen; B Holst; A Inui; J O Jansson; H Kirchner; M Korbonits; B Laferrère; C W LeRoux; M Lopez; S Morin; M Nakazato; R Nass; D Perez-Tilve; P T Pfluger; T W Schwartz; R J Seeley; M Sleeman; Y Sun; L Sussel; J Tong; M O Thorner; A J van der Lely; L H T van der Ploeg; J M Zigman; M Kojima; K Kangawa; R G Smith; T Horvath; M H Tschöp Journal: Mol Metab Date: 2015-03-21 Impact factor: 7.422